SC Pembro, Biotin, 5-yr POLARIX data
from OncoPharm Hosted by John Bossaer
The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use. Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://doi.org/10.1200/OP-25-00693 POLARIX 5-year Data: https://doi.org/10.1200/JCO-25-00925
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 18 minutes long.
When was this OncoPharm episode published?
This episode was published on September 25, 2025.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.